Sarah C. Moser

Sarah C. Moser

Auto-generated profile, based on publicly available information

Sarah C. Moser

Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2021 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MDMariana Paes Dias
Mariana Paes Dias
SMSarah C. Moser
Sarah C. Moser
SGShridar Ganesan
Shridar Ganesan
JJJos Jonkers
Jos Jonkers

7 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
PBPetra ter Brugge
Petra ter Brugge
SMSarah C. Moser
Sarah C. Moser
IBIvan Bièche
Ivan Bièche
PKPetra Kristel
Petra Kristel
SISabrina Ibadioune
Sabrina Ibadioune
EMElisabetta Marangoni
Elisabetta Marangoni
The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer (TNBC), however, the existing methods to identify HRD are controversial and there is a medical need for predictive biomarkers. We assess the in vivo response to platinum agents in 55 patient-derived xenografts (PDX) of TNBC to identify determinants of response. The HRD status, determined from whole genome sequencing, is highly predictive of platinum response. BRCA1 promoter methylation is not associated with response, in part due to residual BRCA1 gene expression and homologous recombination proficiency in different tumours showing mono-allelic methylation. Finally, in 2 cisplatin sensitive tumours we identify mutations in XRCC3 and ORC1 genes that are functionally validated in vitro. In conclusion, our results demonstrate that the genomic HRD is predictive of platinum response in a large cohort of TNBC PDX and identify alterations in XRCC3 and ORC1 genes driving cisplatin response.

13 August 2025 in Nature
Verified
Journal Article
Closed access
SMSarah C. Moser
Sarah C. Moser
AKAnna Khalizieva
Anna Khalizieva
JRJosef Roehsner
Josef Roehsner
EPElisabeth Pottendorfer
Elisabeth Pottendorfer
MKMilo L. Kaptein
Milo L. Kaptein
JJJos Jonkers
Jos Jonkers

2 June 2023 in Science Advances
Verified
Journal Article
Open access
AMAbdelghani Mazouzi
Abdelghani Mazouzi
SMSarah C. Moser
Sarah C. Moser
FAFederico Abascal
Federico Abascal
Bram van den BroekBram van den Broek
Bram van den Broek
MVMartin Del Castillo Velasco-Herrera
Martin Del Castillo Velasco-Herrera
TBThijn R. Brummelkamp
Thijn R. Brummelkamp
DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the machinery involved in the response to ICLs and identified FIRRM/C1orf112 as an indispensable factor in maintaining genome stability. FIRRM deficiency leads to hypersensitivity to ICL-inducing compounds, accumulation of DNA damage during S-G 2 phase of the cell cycle, and chromosomal aberrations, and elicits a unique mutational signature previously observed in HR-deficient tumors. In addition, FIRRM is recruited to ICLs, controls MUS81 chromatin loading, and thereby affects resolution of HR intermediates. FIRRM deficiency in mice causes early embryonic lethality and accelerates tumor formation. Thus, FIRRM plays a critical role in the response to ICLs encountered during DNA replication.

3 March 2025 in Cancer Discovery
Verified
Journal Article
Closed access
SMSarah C. Moser
Sarah C. Moser
JJJos Jonkers
Jos Jonkers
Thirty years ago, the cloning of the first breast cancer susceptibility gene, BRCA1, marked a milestone in our understanding of hereditary breast and ovarian cancers. This discovery initiated extensive research into DNA repair mechanisms, BRCA1-associated tumorigenesis, and therapeutic interventions. Despite these advances, critical questions remain unanswered, such as the evolution of BRCA1-associated tumors and their tissue specificity. These issues hinder the development of effective treatment and prevention strategies, which ultimately aim to improve the quality of life for BRCA1 mutation carriers. In this review, we discuss current knowledge, identify existing gaps, and suggest possible avenues to tackle these challenges. Significance: Here, we explore the impact of three decades of BRCA1 research on the lives of mutation carriers and propose strategies to improve the prevention and treatment of BRCA1-associated cancer.

13 July 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
HRHelen M.R. Robinson
Helen M.R. Robinson
VGVera Grinkevich
Vera Grinkevich
JMJayesh B. Majithiya
Jayesh B. Majithiya
SMSam E. Mann
Sam E. Mann
CMClaire McWhirter
Claire McWhirter
GSGraeme C.M. Smith
Graeme C.M. Smith
Purpose: DNA polymerase theta (Polθ) is the central component of DNA double-strand break repair through microhomology-mediated end joining (MMEJ). Targeting Polθ for cancer therapy has been proposed due to its tumor-selective expression, as well as its role in the survival of homologous recombination–deficient (HRD) cancer cells. Additionally, inhibition of Polθ has been shown to potentiate the effects of DNA damage, such as that caused by poly (ADP-ribose) polymerase (PARP) inhibition. In this study, we present the pharmacologic profile of ART6043, a potent, selective, allosteric, small-molecule inhibitor of the polymerase function of Polθ. Experimental Design: A series of in vitro studies were performed to demonstrate the biochemical and cellular on-target activity of ART6043 in relevant model systems, focusing on combination with PARP inhibitors. Subsequent in vivo studies established a pharmacokinetic/pharmacodynamic/efficacy relationship and explored ART6043’s ability to potentiate the efficacy of PARP inhibitors across a range of cell line-derived xenograft (CDX), patient-derived xenograft (PDX), and genetically engineered mouse models of HRD tumors. Results: ART6043 inhibits Polθ with low nmol/L potency and specifically abrogates MMEJ in cells. Additionally, ART6043 inhibits the survival of HRD cells and potentiates the efficacy of PARP inhibitors in vitro. Furthermore, ART6043 has excellent pharmaceutical properties, is well tolerated, and induces tumor regressions in combination with PARP inhibitors in vivo in HRD models. Conclusions: The data demonstrate strong potential for ART6043 as an anticancer therapeutic for HRD tumors in combination with PARP inhibitors. Based on this, combination therapy of ART6043 with PARP inhibitor treatment is being tested in an ongoing phase I/IIa clinical trial (NCT05898399).